iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference
Insight Molecular Diagnostics (Nasdaq: IMDX) will report Q4 2025 financial results after market close on March 26, 2026, and will host a live Zoom webinar at 2:00 pm PT / 5:00 pm ET the same day with a Q&A session.
Rhea-AI Summary
Insight Molecular Diagnostics (Nasdaq: IMDX) will report Q4 2025 financial results after market close on March 26, 2026, and will host a live Zoom webinar at 2:00 pm PT / 5:00 pm ET the same day with a Q&A session.
An archived replay will be available in the Investors/Events & Presentations section of the company website. Management will also attend the 25th Annual Needham Virtual Healthcare Conference and present in a virtual fireside chat on April 15, 2026.
Positive
- None.
Negative
- None.
Details
News Market Reaction – IMDX
On Mar 20, the day this news came out, IMDX closed 8.67% above the previous close.
Data tracked by StockTitan Argus for the Mar 20 session.
Key Figures
- Earnings release date
- March 26, 2026
- Q4 2025 results release after market close
- Earnings webinar time
- 2:00 pm PT / 5:00 pm ET
- Live Zoom webinar to discuss Q4 2025 results
- Conference edition
- 25th Annual
- Needham Virtual Healthcare Conference
- Conference dates
- April 13–16, 2026
- Needham Virtual Healthcare Conference timeframe
- IMDX presentation date
- April 15, 2026
- Virtual fireside chat at Needham conference
Historical Context
-
Peer-reviewed study showed GraftAssure CM score outperforming other dd-cfDNA measures.
-
Completed key milestones advancing GraftAssureDx toward an FDA De Novo IVD submission.
-
Announced $26.0M registered direct offering at $5.75 per share, indicating dilution.
-
STAR working group paper supported decentralized, absolute dd-cfDNA testing aligned with GraftAssure.
-
Announced participation in JPM Week and BTIG Snowbird investor conferences and meetings.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market closes on Thursday, March 26, 2026. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.
The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDx Q4 2025 Earnings Webinar.
An archived replay will be available after the call concludes on iMDx’s website within the Investors/Events & Presentations section here.
Attendance at 25th Annual Needham Virtual Healthcare Conference
Separately, on April 15th, Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 25th Annual Needham Virtual Healthcare Conference, taking place from April 13-16, 2026.
Event: 25th Annual Needham Virtual Healthcare Conference
Presentation Date: April 15, 2026
Format: Virtual fireside chat
Webcast: Click here
iMDx management will also be conducting one-on-one meetings with investors at the conference. Investors wishing to book a meeting are encouraged to reach out to their Needham sales representative.
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.
GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.
Investor Contact:
Alexandra Grossman
LifeSci Advisors LLC
alex@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.